NEW YORK, NY--(Marketwired - Aug 19, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Vincent S. Dugan as Director of National Sales and Mr. John Huber III as interim Chief Financial Officer. The focus being to strengthen the launch of the establishment of additional cellular labs, all being cGTP, FDA registered labs, in hospitals and ambulatory surgical centers across the country. IntelliCell will be responsible for training staff on site and will maintain Quality Assurance of all labs from our headquarters in New York.
Mr. Vincent S. Dugan has worked for the past 11 years in the sales of Orthopedic Medical Devices. Vincent has successfully been involved in the launch of over 20 new orthopedic devices from companies such as Johnson & Johnson, Pivot Medical, Checkpoint Surgical, and ConforMis. Besides providing year after year of consistent growth, Vincent had been involved in the recruiting, training, and hiring of countless sales professionals. Through years of relationships, Vincent has developed a national network of healthcare distributors that he will recruit to help IntelliCell place its technology at Ambulatory Surgery Centers and Hospitals throughout the United States.
Mr. John Huber III is a managing partner at Mango & Huber CPAs in Westfield, New Jersey and has been a practicing CPA in the New York/New Jersey metropolitan area for the last 30 years. His firm has provided outsourced CFO services for several SEC companies over the last 10 years. His firm's experience with financial reporting and accounting controls will enable IntelliCell BioSciences, Inc. to manage the increased activity stemming from the placement of additional labs using the patented technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a key point for IntelliCell BioSciences as it launches the establishment of its FDA registered inspected cGTP cellular lab that utilizes its patented technology. The target is orthopedics and pain physicians. With Vincent's experience in this area for over a decade, IntelliCell is excited and believes that it will be successful in establishing its Cellular Lab in Ambulatory Surgery Centers and Hospitals. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with orthopedics and pain a new and improved approach to gaining significant improvements in their qualities of life. John Huber brings his expertise in the financial area to help manage the finances of IntelliCell."
According to Vincent Dugan, "There is a great demand amongst healthcare professionals and patients to provide better outcomes through the use of biologics. The IntelliCell technology is the latest generation of stem cell technology and works to provide improved patient outcomes and satisfaction. We look forward to making this technology available to Ambulatory Surgery Centers and Hospitals across the United States."
John Huber said, "Our firm is looking forward to the challenge of providing top quality CFO services to a medical tech company that has real growth potential and a niche that could very well set a new precedent in health care. The company is at a critical point in its development and will need to strengthen its financial reporting systems."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.